Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such a… Read more
Viva Biotech Holdings (VBIZF) - Net Assets
Latest net assets as of June 2025: $3.91 Billion USD
Based on the latest financial reports, Viva Biotech Holdings (VBIZF) has net assets worth $3.91 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.88 Billion) and total liabilities ($2.98 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.91 Billion |
| % of Total Assets | 56.77% |
| Annual Growth Rate | 63.02% |
| 5-Year Change | 1.58% |
| 10-Year Change | N/A |
| Growth Volatility | 192.71 |
Viva Biotech Holdings - Net Assets Trend (2016–2024)
This chart illustrates how Viva Biotech Holdings's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Viva Biotech Holdings (2016–2024)
The table below shows the annual net assets of Viva Biotech Holdings from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.82 Billion | +3.48% |
| 2023-12-31 | $3.69 Billion | +2.31% |
| 2022-12-31 | $3.60 Billion | -7.89% |
| 2021-12-31 | $3.91 Billion | +4.17% |
| 2020-12-31 | $3.76 Billion | +111.37% |
| 2019-12-31 | $1.78 Billion | +606.88% |
| 2018-12-31 | $251.44 Million | +64.60% |
| 2017-12-31 | $152.76 Million | +99.68% |
| 2016-12-31 | $76.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Viva Biotech Holdings's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1028.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $367.00K | 0.01% |
| Other Comprehensive Income | $212.73 Million | 5.59% |
| Other Components | $3.72 Billion | 97.74% |
| Total Equity | $3.80 Billion | 100.00% |
Viva Biotech Holdings Competitors by Market Cap
The table below lists competitors of Viva Biotech Holdings ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prism Johnson Limited
NSE:PRSMJOHNSN
|
$305.09 Million |
|
SOLiD Inc
KQ:050890
|
$305.10 Million |
|
ECOVE Environment Corp
TWO:6803
|
$305.16 Million |
|
Garware Technical Fibres Limited
NSE:GARFIBRES
|
$305.20 Million |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
$304.87 Million |
|
Takamatsu Construction Group Co., Ltd.
PINK:TAKMF
|
$304.85 Million |
|
0N01
LSE:0N01
|
$304.75 Million |
|
Krispy Kreme Inc
NASDAQ:DNUT
|
$304.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Viva Biotech Holdings's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,687,912,000 to 3,802,377,000, a change of 114,465,000 (3.1%).
- Net income of 167,294,000 contributed positively to equity growth.
- Share repurchases of 23,019,000 reduced equity.
- Other comprehensive income decreased equity by 29,810,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $167.29 Million | +4.4% |
| Share Repurchases | $23.02 Million | -0.61% |
| Other Comprehensive Income | $-29.81 Million | -0.78% |
| Other Changes | $1.00 | +0.0% |
| Total Change | $- | 3.10% |
Book Value vs Market Value Analysis
This analysis compares Viva Biotech Holdings's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.17x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.87x to 0.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.05 | $0.30 | x |
| 2017-12-31 | $0.10 | $0.30 | x |
| 2018-12-31 | $0.21 | $0.30 | x |
| 2019-12-31 | $1.20 | $0.30 | x |
| 2020-12-31 | $2.39 | $0.30 | x |
| 2021-12-31 | $1.99 | $0.30 | x |
| 2022-12-31 | $1.88 | $0.30 | x |
| 2023-12-31 | $1.82 | $0.30 | x |
| 2024-12-31 | $1.78 | $0.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Viva Biotech Holdings utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.42%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.85x
- Recent ROE (4.40%) is below the historical average (12.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 31.99% | 25.36% | 0.95x | 1.33x | $16.82 Million |
| 2017 | 49.92% | 51.44% | 0.73x | 1.32x | $60.98 Million |
| 2018 | 36.01% | 43.11% | 0.40x | 2.11x | $65.41 Million |
| 2019 | 14.96% | 82.30% | 0.17x | 1.07x | $88.13 Million |
| 2020 | -10.30% | -55.51% | 0.09x | 2.17x | $-762.56 Million |
| 2021 | 7.35% | 13.67% | 0.26x | 2.06x | $-103.79 Million |
| 2022 | -14.66% | -22.21% | 0.30x | 2.20x | $-888.95 Million |
| 2023 | -3.15% | -5.39% | 0.29x | 2.02x | $-484.90 Million |
| 2024 | 4.40% | 8.42% | 0.28x | 1.85x | $-212.94 Million |
Industry Comparison
This section compares Viva Biotech Holdings's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Viva Biotech Holdings (VBIZF) | $3.91 Billion | 31.99% | 0.76x | $304.96 Million |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |